Exelixis

Major pharmaceutical companies including AstraZeneca, Novartis, and Astellas are defending patents for blockbuster drugs like Lynparza, Entresto, and Xtandi against generic manufacturers in early 2025.

Bristol-Myers Squibb, Exelixis, and Novartis are collaborating on the Pan-Tumor Rollover Study to evaluate the long-term safety of nivolumab monotherapy and its combinations across various tumor types.

A new comprehensive report analyzes over 200 pipeline drugs from 180+ companies targeting metastatic hormone refractory prostate cancer, highlighting the extensive research efforts in this challenging therapeutic area.

Innovent's IBI3020, a dual-payload ADC targeting CEACAM5, has begun first-in-human trials for solid tumors, marking a significant milestone in next-generation cancer therapeutics.

Zanzalintinib combined with nivolumab demonstrated a 63% objective response rate and 90% disease control rate in previously untreated advanced clear cell renal cell carcinoma patients.

Exelixis has begun dose-escalation in a first-in-human Phase 1 trial of XB628, a first-in-class bispecific antibody targeting both NKG2A and PD-L1 in patients with recurrent advanced or metastatic solid tumors.

Insilico Medicine closed an oversubscribed Series E financing round totaling $123 million, led by Value Partners Group, to advance its AI-driven drug discovery platform and clinical pipeline.

Ryvu's RVU305, a brain-permeable MTA-cooperative PRMT5 inhibitor, demonstrates significant tumor growth inhibition in MTAP-deleted cancer models and enhances responses when combined with anti-PD-1 antibodies.

DelveInsight's latest report reveals a robust pipeline with over 195 companies developing 200+ therapies for colorectal cancer, highlighting significant innovation in targeted treatments and immunotherapies.

Insilico Medicine has raised $110 million in Series E financing led by Value Partners Group, valuing the company at over $1 billion and officially achieving unicorn status.